The pulmonary complications of cirrhosis, PoPH and HPS, are associated with markedly reduced BMP9 and BMP10 and increased sEng levels, suggesting that supplementation with exogenous ligands might be a therapeutic approach for PoPH and HPS. This evidence concerns the gene GDF2 and Pulmonary arterial hypertension associated with portal hypertension.